RECURSION PHARMACEUTICALS-A (RXRX)
US75629V1044 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 391.56M | 549.90M | 285.10M | 262.10M | 69.90M | |||
| Marketable Securities | N/A | 0.00 | 231.40M | 0.00 | N/A | |||
| Receivables | 3.09M | 2.80M | 9.10M | 200.00K | 200.00K | |||
| Other Current Assets | 43.48M | 17.10M | 9.10M | 4.20M | 6.40M | |||
| Total Current Assets | 438.14M | 569.80M | 534.70M | 266.40M | 76.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 120.17M | 121.40M | 64.70M | 26.00M | 24.40M | |||
| Goodwill | 52.06M | 800.00K | 800.00K | 800.00K | N/A | |||
| Intangibles | 36.44M | 1.30M | 1.40M | 1.70M | 0.00 | |||
| Other Non-Current Assets | 6.89M | 7.90M | 8.70M | 3.70M | 700.00K | |||
| Total Non-Current Assets | 215.56M | 131.50M | 75.60M | 32.20M | 25.00M | |||
| TOTAL ASSETS | 653.70M | 701.30M | 610.30M | 298.60M | 101.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 41.00K | 100.00K | 100.00K | 1.10M | 100.00K | |||
| Accrued Expenses | 52.75M | 38.90M | 33.70M | 11.00M | 5.30M | |||
| Accounts Payable | 3.95M | 4.60M | 2.80M | 1.10M | 1.30M | |||
| Other Current Liabilities | 36.43M | 56.70M | 10.00M | 10.00M | 0.00 | |||
| Total Current Liabilities | 93.17M | 100.30M | 46.70M | 23.10M | 6.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.10M | 500.00K | 600.00K | 11.40M | 12.40M | |||
| Deferred Taxes/Income | 1.34M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 94.65M | 114.70M | 20.10M | 22.00M | 5.50M | |||
| Total Non-Current Liabilities | 97.09M | 115.20M | 20.70M | 33.50M | 17.90M | |||
| TOTAL LIABILITIES | 190.26M | 215.50M | 67.40M | 56.60M | 24.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -967.62M | -639.60M | -400.10M | -213.60M | -126.60M | |||
| Additional Paid In Capital | 1.43B | 1.13B | 943.10M | 7.30M | 2.30M | |||
| Common Shares | 2.00K | 0.00 | 0.00 | 448.30M | 201.10M | |||
| Other Shareholders' Equity | N/A | 0.00 | -100.00K | 0.00 | N/A | |||
| Shares Outstanding | 233.81M | 191.00M | 170.30M | 162.20M | 162.20M | |||
| Tangible Book Value per Share | 1.60 | 2.53 | 3.17 | -1.29 | -0.77 | |||
| Total Shareholders' Equity | 463.44M | 485.80M | 542.90M | 242.00M | 76.80M | |||
| TOTAL LIABILITIES AND EQUITY | 653.70M | 701.30M | 610.30M | 298.60M | 101.40M | |||
| Statistics | ||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.05 | 0.16 | |||
| Current Ratio | 4.70 | 5.68 | 11.45 | 11.53 | 11.40 | |||
| Return On Assets (ROA) | -50.19% | -34.15% | -30.56% | -29.14% | -61.03% | |||
| Return On Equity (ROE) | -70.79% | -49.30% | -34.35% | -35.95% | -80.57% | |||
All data in USD